1. Belgium Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Fagron N.V.

Fagron N.V.

FAGR.BR
Fagron N.V.BE flagEuronext Brussels
24.05
EUR
-0.55
- -
1.76BMarket Cap
Fagron N.V.
FAGR.BR
(Euronext Brussels)

Recent

price

24.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
13.09
15.15
10.24
10.35
13.46
12.69
7.82
6.04
6.57
7.45
7.71
7.9
9.38
10.45
11.95
13.03
Revenue per Share
0.69
0.87
1.33
-0.97
0.49
-6.01
-0.38
0.65
0.59
0.57
0.83
0.84
0.96
0.97
1.1
1.25
Basic EPS, GAAP
0.71
2.22
2.06
1.91
3.06
2.18
1.25
1.17
1.02
1.07
1.29
1.08
1.5
1.18
0.95
1.71
Free Cash Flow per Basic Share
0.33
0.41
0.46
0.57
0.67
0.93
- -
- -
0.1
0.12
0.08
0.18
0.2
0.25
0.29
0.36
Dividend per Share
12.64
13.07
13.77
12.2
12
5.68
7.17
6.04
6.53
7.01
7.79
8.48
9.22
10.01
10.82
11.82
Book Value per Share
-2.36
-4.47
-5.24
-7.41
-12.59
-14.11
-4.04
-2.22
-2.53
-2.39
-1.82
-1.18
-0.73
-0.21
-0.04
-0.2
Tangible Book Value per Share
32
32
33
33
33
34
54
72
72
72
72
73
73
73
73
73
Basic Weighted Avg Shares
424
492
338
343
447
428
422
434
472
535
556
574
684
763
872
952
Sales/Revenue/Turnover
8.49
9.38
15.91
19.17
21.6
18.71
16.35
17.62
16.23
16.36
16.62
15.67
14.79
14.77
15.41
15.49
Operating Margin (%)
13
15
14
9
16
14
18
15
16
26
27
26
31
35
36
44
Depreciation Expense
22
28
44
-32
16
-202
-21
47
42
41
60
61
70
71
81
91
Net Income, GAAP
25.21
24.11
- -
14.33
38.17
- -
- -
15.93
21.07
20.32
18.56
20.1
20.17
15.87
22.34
22.17
Effective Tax Rate (%)
5.3
5.72
13.01
-9.37
3.63
-47.32
-4.87
10.76
9.01
7.68
10.72
10.63
10.18
9.25
9.24
9.56
Profit Margin (%)
78
-213
49
6
7
-539
6
58
12
47
22
89
147
161
168
244
Working Capital
215
4
301
369
552
4
290
284
266
351
284
321
380
357
376
457
LT Debt
208
222
245
155
157
-65
153
185
210
246
258
325
411
468
505
556
Total Equity
6.56
7.22
- -
9.69
9.01
- -
- -
10.3
11.5
11.4
11.48
10.79
10.53
11.03
11.53
11.48
Return on Invested Capital (%)
7.03
5.2
- -
-2.81
3.25
- -
- -
7.12
6.63
5.91
7.47
7.14
7.64
7.6
8.21
8.42
Return on Capital (%)
10.98
6.75
9.99
-7.48
4.04
-68.6
-7.11
11.38
9.42
8.44
11.19
10.36
10.81
10.06
10.6
11.01
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-19.51%
16.88%
10.07%
Free Cash Flow
9.29%
12.65%
80.39%
Net Income, GAAP
-33.89%
8.99%
12.99%
Sales/Revenue/Turnover
8.5%
11.49%
9.2%
Total Cash Common Dividend
- -
40.38%
23.55%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
763
2024
- -
- -
- -
- -
872
2025
- -
- -
- -
- -
952

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.97
2024
- -
- -
- -
- -
1.1
2025
- -
- -
- -
- -
1.25

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.25
2024
- -
- -
- -
- -
0.29
2025
- -
- -
- -
- -
0.36
Similar Companies
Eisai Co., Ltd. (4523.T)
Biotest AG (BIO1.F)
Ind-Swift Limited (INDSWFTLTD.NS)
Genix Pharmaceuticals Corporation (GENPF)
Upexi, Inc. (GRVI)
Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ)
Business
Fagron NV (FAGR.BR) is a Belgium-based pharmaceutical compounding company that develops, markets and distributes specialized healthcare products and services to hospitals, pharmacies, clinics and patients worldwide; it operates through three segments including Essentials, which supplies pharmaceutical raw materials, compounding equipment, packaging and supplies; Brands, which offers innovative semi-finished products, pharmaceutical-grade vehicles such as emulsions, creams, Pentravan transdermal bases and SyrSpend oral suspending vehicles, formulations and total concepts; and Compounding Services, which provides sterile and non-sterile ready-to-use personalized compounded medications. Founded in 1990 in Rotterdam, Netherlands, with registered offices in Nazareth, Belgium, operational headquarters in Rotterdam and activities spanning over 30 countries across Europe, North America, Latin America, Asia-Pacific, Africa and other regions, Fagron serves more than 150,000 customers with approximately 4,000 employees. Recent developments include multiple strategic acquisitions in 2025 such as CareFirst Specialty Pharmacy and UCP in North America, Injeplast and Purifarma in Brazil, Amara in Poland, Magilab in Hungary, Bella Corp in Australia, Active Pharma Supplies in the UK and Uni-Chem and SB Trade in Serbia to strengthen market positioning and compounding capabilities; execution of 10 acquisitions in 2025 overall with mid-teens million euro annual revenues at high margins; a new U.S. dollar credit facility for North American growth; expansion investments including a $29 million upgrade to Anazao's 503B facility in Las Vegas for $150 million additional capacity by 2028; and an upgraded growth strategy emphasizing global leadership in essentials, brands acceleration, sterile services expansion and non-sterile optimization presented at its 2025 Capital Markets Day.